Navigation Links
Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting
Date:9/27/2010

Newtown, PA, September 27, 2010 Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii. In vivo studies show that Ex-RAD, upon oral administration, produced a significant increase in survival versus placebo-treated groups in mice exposed to lethal whole body irradiation (WBI), for both prophylactic pre-treatment and mitigation post-treatment. Ex-RAD is the only known oral radioprotectant that has shown such activity in animal model systems.

Collectively, these presentations demonstrate the ability of Ex-RAD to provide radioprotective benefit by injection and oral delivery, an in-depth understanding of the kinetics and metabolism of Ex-RAD, and radioprotective benefit to human bone marrow, as well as the gastrointestinal and hematopoietic systems in mice.

Onconova, a biopharmaceutical company developing novel chemical entities to treat cancer and protect normal cells, is developing Ex-RAD, a novel radioprotectant with potential utility in bio-defense or bio-terrorism, which could prove useful as a prophylactic agent for first-responder protection from the harmful effects of radiation from nuclear accidents or weapons of mass destruction (WMD).

These presentations result from an on-going Onconova collaboration among investigators at a number of institutions: AFRRI, (The Armed Forces Radiobiology Research Institute) a part of the Uniformed Services University of the Health Sciences (USUHS); Georgetown University, Department of Biochemistry and Molecular & Cellular Biology; Long Island University, Arnold & Marie Schwartz College of Pharmacy; and the Department of Oncological Sciences, Mt. Sinai School of Medicine.

Summary of Oral Ex-RAD Findings

The results from a prophylactic radioprotection study in mice demonstrated that Ex-RAD dosed orally or by injection prior to lethal whole body irradiation (WBI) produced significant enhancement in survival for both Ex-RAD treated groups versus placebo.

Results from the radiomitigation experiment (where the drug is administered after exposure to lethal radiation), using both injection and oral methods of delivery demonstrated that Ex-RAD treated animals had comparably high rates of survival in both groups.

Hence, oral Ex-RAD was found to be effective in both prophylactic pre-treatment and mitigation post-treatment settings.

"Years of collaborative work are resulting in great progress with Ex-RAD in the laboratory and the clinic and Ex-RAD is the focus of several posters and a key presentation within the RSS scientific and educational track," said Manoj Maniar, PhD, Senior Vice President for Product Development of Onconova. "We are very excited to see the acceleration and new developments within radioprotection, specifically in oral prophylaxis and treatment. Ex-RAD holds a unique position among developing products with the potential to benefit people exposed to whole body radiation."

Onconova oral presentation and poster sessions on Ex-RAD at the Radiation Research Society meeting:

Oral Presentation

WEDNESDAY, SEPTEMBER 29, 2010

  • No. MS701 (Mini-Symposium Presentation, 10:15 AM-12:15 PM) Radioprotection and Radiomitigation Properties of Ex-RAD Upon Oral Administration Manoj Maniar1, Ramesh Kumar1, Bo-Hyun Moon2, David Taft3, Kamal Datta2; 1Onconova Therapeutics, Inc., 2Georgetown University, Department of Biochemistry and Molecular & Cellular Biology and Lombardi Comprehensive Cancer Center, 3Long Island University, Arnold & Marie Schwartz College of Pharmacy

Poster Sessions Radiation Protection Protection / Mitigators / Treatment

SUNDAY, SEPTEMBER 26, 2:00 pm-2:45 pm, 2010, Haleakala Foyer

  • PS.1.56 Radioprotection and Radiomitigation Properties of Ex-RAD Upon Oral Administration Manoj Maniar1, Ramesh Kumar1, Bo-Hyun Moon2, David Taft3, Kamal Datta2; 1Onconova Therapeutics, Inc., 2Georgetown University, Department of Biochemistry and Molecular & Cellular Biology and Lombardi Comprehensive Cancer Center, 3Long Island University, Arnold & Marie Schwartz College of Pharmacy

  • PS1.10Recovery from radiation-induced hematopoietic and gastrointestinal sub-syndromes by Ex-RAD in murine model, Sanchita P. Ghosh1, Shilpa Kulkarni1, Michael W. Perkins1, Kevin Hieber1, Ethery Amari1, Kristen Gambles1, Manoj M. Maniar2, Thomas Seed1, and K. Sree Kumar1; 1Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, 2Onconova Therapeutics Inc.

  • PS1.73Radioprotection of human bone marrow by ON 01210.Na (Ex-RAD ) through AKT-mediated signaling pathway Anthony D. Kang1,2, Stephen C.Cosenza1,3, Ramana Reddy1,3, E. Premkumar Reddy1,3 1Fels Institute for Cancer Research and Molecular Biologyand 2Armed Forces Radiobiology Research Institute, 3Department of Oncological Sciences, Mt. Sinai School of Medicine

Poster Sessions Experimental Therapeutics and Translational Research

WEDNESDAY, SEPTEMBER 29, 5:30 PM-6:15 PM, 2010 Haleakala Foyer

  • PS7.64 Disposition of Ex-RAD (ON 01210.Na), a new radioprotectant, in the isolated perfused rat liver model; Chen Ren1, Mitalee Tamhane2, David Taft2, Manoj Maniar1, 1Onconova Therapeutics, Inc., 2Long Island University

  • PS7.20Metabolic disposition of Ex-RAD (ON 01210.Na), a novel radioprotectant Chen Ren1, Mitalee Tamhane2, Glenn Fegley1, David Taft2, Manoj Maniar1; 1Onconova Therapeutics, Inc., 2Long Island University, Brooklyn, NY


'/>"/>

Contact: Katrhyn Morris
kathryn@proncall.com
845-635-9828
PR on Call
Source:Eurekalert

Related medicine news :

1. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
2. Study says therapeutics for trauma patients may not be effective due to an infection
3. Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference
4. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
5. ACS Webinar focuses on drug discovery process for small molecule therapeutics
6. Talecris Biotherapeutics Hires Nimish Shah as Vice President, Federal Government Relations
7. US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications
8. JDP Therapeutics, Inc. Appoints Christopher M. Cashman to Board of Directors
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
11. FAB-HOMES™ Presents First Passive House Collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
Breaking Medicine Technology: